keyword
MENU ▼
Read by QxMD icon Read
search

Bonomo Robert

keyword
https://www.readbyqxmd.com/read/28536161/correction-for-evans-et-al-informing-antibiotic-treatment-decisions-evaluating-rapid-molecular-diagnostics-to-identify-susceptibility-and-resistance-to-carbapenems-against-acinetobacter-spp-in-primers-iii
#1
Scott R Evans, Andrea M Hujer, Hongyu Jiang, Carol B Hill, Kristine M Hujer, Jose R Mediavilla, Claudia Manca, Thuy Tien T Tran, T Nicholas Domitrovic, Paul G Higgins, Harald Seifert, Barry N Kreiswirth, Robin Patel, Michael R Jacobs, Liang Chen, Rangarajan Sampath, Thomas Hall, Christine Marzan, Vance G Fowler, Henry F Chambers, Robert A Bonomo
No abstract text is available yet for this article.
June 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28521000/the-ecology-of-extended-spectrum-%C3%AE-lactamases-esbls-in-the-developed-world
#2
Yohei Doi, Alina Iovleva, Robert A Bonomo
Background: Since the initial appearance in the 1980s, Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) have increased in prevalence and emerged as a major antimicrobial-resistant pathogen. The source of these antimicrobial-resistant bacteria in the developed world is an area of active investigation. Methods: A standard internet search was conducted with a focus on the epidemiology and potential sources of ESBL-producing Enterobacteriaceae in the developed world...
April 1, 2017: Journal of Travel Medicine
https://www.readbyqxmd.com/read/28482143/discovery-of-1-hydroxypyridine-2-1h-thione-6-carboxylic-acid-as-a-first-in-class-low-cytotoxic-nanomolar-metallo-%C3%AE-lactamase-inhibitor
#3
Woo Shik Shin, Alexander Bergstrom, Robert A Bonomo, Michael W Crowder, Ramaiah Muthyala, Yuk Yin Sham
VIM-2 is one of the most common carbapenem-hydrolyzing metallo β-lactamases (MBL) found in many drug-resistant Gram-negative bacterial strains. Currently, there is a lack of effective lead compounds with optimal therapeutic potential within our drug development pipeline. Here we report the discovery of 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid (3) as a first-in-class metallo β-lactamase inhibitor (MBLi) with a potent inhibition Ki of 13 nm against VIM-2 that corresponds to a remarkable 0.99 ligand efficiency...
May 8, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28468855/simple-screening-for-carbapenemase-producing-enterobacteriaceae-by-moxalactam-susceptibility-testing
#4
Waka Imai, Masakazu Sasaki, Kotaro Aoki, Yoshikazu Ishii, Robert A Bonomo, Tse Hsien Koh, Hinako Murakami, Toshisuke Morita, Kazuhiro Tateda
The increase of carbapenemase producing Enterobacteriaceae (CPE) is a serious concern worldwide (1-7).….
May 3, 2017: Journal of Clinical Microbiology
https://www.readbyqxmd.com/read/28461314/ndm-5-and-oxa-181-beta-lactamases-a-significant-threat-continues-to-spread-in-the-americas
#5
Laura J Rojas, Andrea M Hujer, Susan D Rudin, Meredith S Wright, T Nicholas Domitrovic, Steven H Marshall, Kristine M Hujer, Sandra S Richter, Eric Cober, Federico Perez, Mark D Adams, David van Duin, Robert A Bonomo
Among Gram-negative bacteria, carbapenem resistant (CR) infections pose a serious and life threatening challenge. Here, the CRACKLE network reports a sentinel detection and characterization of a CR Klebsiella pneumoniae ST147 isolate harboring blaNDM-5 and blaOXA-181, from a young man who underwent abdominal surgery in India. blaNDM-5 was located on an IncFII plasmid of ≈ 90Kb, while blaOXA-181 was chromosomally encoded. Resistome and genome analysis demonstrated multiple copies of the transposable element IS26 and a "hotspot region" in the IncFII plasmid...
May 1, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28442293/effect-of-appropriate-combination-therapy-on-mortality-of-patients-with-bloodstream-infections-due-to-carbapenemase-producing-enterobacteriaceae-increment-a-retrospective-cohort-study
#6
Belén Gutiérrez-Gutiérrez, Elena Salamanca, Marina de Cueto, Po-Ren Hsueh, Pierluigi Viale, José Ramón Paño-Pardo, Mario Venditti, Mario Tumbarello, George Daikos, Rafael Cantón, Yohei Doi, Felipe Francisco Tuon, Ilias Karaiskos, Elena Pérez-Nadales, Mitchell J Schwaber, Özlem Kurt Azap, Maria Souli, Emmanuel Roilides, Spyros Pournaras, Murat Akova, Federico Pérez, Joaquín Bermejo, Antonio Oliver, Manel Almela, Warren Lowman, Benito Almirante, Robert A Bonomo, Yehuda Carmeli, David L Paterson, Alvaro Pascual, Jesús Rodríguez-Baño
BACKGROUND: The best available treatment against carbapenemase-producing Enterobacteriaceae (CPE) is unknown. The objective of this study was to investigate the effect of appropriate therapy and of appropriate combination therapy on mortality of patients with bloodstream infections (BSIs) due to CPE. METHODS: In this retrospective cohort study, we included patients with clinically significant monomicrobial BSIs due to CPE from the INCREMENT cohort, recruited from 26 tertiary hospitals in ten countries...
April 21, 2017: Lancet Infectious Diseases
https://www.readbyqxmd.com/read/28428984/a-comparison-of-molecular-typing-methods-applied-to-enterobacter-cloacae-complex-hsp60-sequencing-rep-pcr-and-mlst
#7
Roberto A Viau, Lee M Kiedrowski, Barry N Kreiswirth, Mark Adams, Federico Perez, Dror Marchaim, Dubert M Guerrero, Keith S Kaye, Latania K Logan, Maria Virginia Villegas, Robert A Bonomo
Molecular typing using repetitive sequenced-based PCR (rep-PCR) and hsp60 sequencing were applied to a collection of diverse Enterobacter cloacae complex isolates. To determine the most practical method for reference laboratories, we analyzed 71 E. cloacae complex isolates from sporadic and outbreak occurrences originating from 4 geographic areas. While rep-PCR was more discriminating, hsp60 sequencing provided a broader and a more objective geographical tracking method similar to multilocus sequence typing (MLST)...
2017: Pathogens & Immunity
https://www.readbyqxmd.com/read/28418318/carbapenem-resistant-enterobacter-cloacae-in-patients-from-the-us-veterans-health-administration-2006-2015
#8
Brigid M Wilson, Nadim G El Chakhtoura, Sachin Patel, Elie Saade, Curtis J Donskey, Robert A Bonomo, Federico Perez
We analyzed carbapenem-resistant Enterobacteriaceae (CRE) trends among patients from the US Veterans Health Administration (VHA). After the emergence of CRE in the eastern United States, resistance rates remained stable in Klebsiella pneumoniae but increased in Enterobacter cloacae complex, suggesting a "second epidemic". VHA offers a vantage point for monitoring nationwide CRE trends.
May 2017: Emerging Infectious Diseases
https://www.readbyqxmd.com/read/28398924/factors-leading-to-transmission-risk-of-acinetobacter-baumannii
#9
Kerri A Thom, Clare Rock, Sarah S Jackson, J Kristie Johnson, Arjun Srinivasan, Laurence S Magder, Mary-Claire Roghmann, Robert A Bonomo, Anthony D Harris
OBJECTIVES: To identify patient and healthcare worker factors associated with transmission risk of Acinetobacter baumannii during patient care. DESIGN: Prospective cohort study. SETTING: ICUs at a tertiary care medical center. PATIENTS: Adult ICU patients known to be infected or colonized with A. baumannii. MEASUREMENTS AND MAIN RESULTS: Cultures of skin, respiratory tract, and the perianal area were obtained from participants and evaluated for the presence of A...
April 10, 2017: Critical Care Medicine
https://www.readbyqxmd.com/read/28350903/advancing-diagnostics-to-address-antibacterial-resistance-the-diagnostics-and-devices-committee-of-the-antibacterial-resistance-leadership-group
#10
Ephraim L Tsalik, Elizabeth Petzold, Barry N Kreiswirth, Robert A Bonomo, Ritu Banerjee, Ebbing Lautenbach, Scott R Evans, Kimberly E Hanson, Jeffrey D Klausner, Robin Patel
Diagnostics are a cornerstone of the practice of infectious diseases. However, various limitations frequently lead to unmet clinical needs. In most other domains, diagnostics focus on narrowly defined questions, provide readily interpretable answers, and use true gold standards for development. In contrast, infectious diseases diagnostics must contend with scores of potential pathogens, dozens of clinical syndromes, emerging pathogens, rapid evolution of existing pathogens and their associated resistance mechanisms, and the absence of gold standards in many situations...
March 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28350901/gram-negative-bacterial-infections-research-priorities-accomplishments-and-future-directions-of-the-antibacterial-resistance-leadership-group
#11
Yohei Doi, Robert A Bonomo, David C Hooper, Keith S Kaye, James R Johnson, Cornelius J Clancy, Joshua T Thaden, Martin E Stryjewski, David van Duin
Antimicrobial resistance in pathogenic gram-negative bacteria is one of the most pressing challenges in the field of infectious diseases and is one of 4 key areas of unmet medical need identified by the Antibacterial Resistance Leadership Group (ARLG). The mission of the Gram-Negative Committee is to advance our knowledge of these challenging infections and implement studies to improve patient outcomes. Studies have fallen primarily into 2 broad categories: prospective cohort studies and interventional trials...
March 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28350898/leading-antibacterial-laboratory-research-by-integrating-conventional-and-innovative-approaches-the-laboratory-center-of-the-antibacterial-resistance-leadership-group
#12
Claudia Manca, Carol Hill, Andrea M Hujer, Robin Patel, Scott R Evans, Robert A Bonomo, Barry N Kreiswirth
The Antibacterial Resistance Leadership Group (ARLG) Laboratory Center (LC) leads the evaluation, development, and implementation of laboratory-based research by providing scientific leadership and supporting standard/specialized laboratory services. The LC has developed a physical biorepository and a virtual biorepository. The physical biorepository contains bacterial isolates from ARLG-funded studies located in a centralized laboratory and they are available to ARLG investigators. The Web-based virtual biorepository strain catalogue includes well-characterized gram-positive and gram-negative bacterial strains published by ARLG investigators...
March 15, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28348157/exploring-the-landscape-of-diazabicyclooctane-dbo-inhibition-avibactam-avi-inactivation-of-per-2-%C3%AE-lactamase
#13
Melina Ruggiero, Krisztina M Papp-Wallace, Magdalena A Taracila, Maria F Mojica, Christopher R Bethel, Susan D Rudin, Elise T Zeiser, Gabriel Gutkind, Robert A Bonomo, Pablo Power
PER β-lactamases are an emerging family of extended-spectrum β-lactamases (ESBL) found in Gram negative bacteria. PER β-lactamases are unique among class A enzymes as they possess an inverted Ω loop and extended B3 β-strand. These singular structural differences are hypothesized to contribute to their hydrolytic profile against oxyimino-cephalosporins (e.g., cefotaxime and ceftazidime). Here, we tested the ability of avibactam (AVI), a novel non-β-lactam β-lactamase inhibitor to inactivate PER-2. Interestingly, the PER-2 inhibition constants (i...
March 27, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28329350/multicenter-evaluation-of-ceftolozane-tazobactam-for-serious-infections-caused-by-carbapenem-resistant-pseudomonas-aeruginosa
#14
Jose M Munita, Samuel L Aitken, William R Miller, Federico Perez, Rossana Rosa, Luis A Shimose, Paola N Lichtenberger, Lilian M Abbo, Rupali Jain, Masayuki Nigo, Audrey Wanger, Rafael Araos, Truc T Tran, Javier Adachi, Robert Rakita, Samuel Shelburne, Robert A Bonomo, Cesar A Arias
A multicenter, retrospective study of patients infected with carbapenem-resistant Pseudomonas aeruginosa who were treated with ceftolozane/tazobactam was performed. Among 35 patients, pneumonia was the most common indication and treatment was successful in 26 (74%). Treatment failure was observed in all cases where isolates demonstrated ceftolozane-tazobactam minimum inhibitory concentrations ≥8 μg/mL.
March 14, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/28289035/wck-5107-zidebactam-wck-5153-novel-inhibitors-of-pbp2-showing-potent-%C3%AE-lactam-enhancer-activity-against-pseudomonas-aeruginosa-including-multidrug-resistant-metallo-%C3%AE-lactamase-producing-high-risk-clones
#15
Bartolome Moya, Isabel M Barcelo, Sachin Bhagwat, Mahesh Patel, German Bou, Krisztina M Papp-Wallace, Robert A Bonomo, Antonio Oliver
Zidebactam and WCK 5153 are novel β-lactam enhancers that are bicyclo-acyl hydrazides (BCH), derivatives of diazabicyclooctane (DBO) scaffold, targeted for the treatment of serious infections caused by highly drug-resistant Gram-negative pathogens. In this report, we determined the PBP inhibition profiles and the antimicrobial activity of zidebactam and WCK 5153 against P. aeruginosa, including multidrug-resistant (MDR) metallo-β-lactamase (MBL)-producing high-risk clones. MICs and time-kill assays were conducted for zidebactam, WCK 5153 and antipseudomonal β-lactams using wild-type PAO1 strain, MexAB-OprM-hyperproducing (mexR), porin deficient (oprD) and AmpC-hyperproducing (dacB) derivatives of PAO1 and MBL-expressing clinical strains, ST175 (blaVIM-2) and ST111 (blaVIM-1)...
March 13, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28270585/transcriptome-remodeling-of-acinetobacter-baumannii-during-infection-and-treatment
#16
Meredith S Wright, Michael R Jacobs, Robert A Bonomo, Mark D Adams
Acinetobacter baumannii is an increasingly common multidrug-resistant pathogen in health care settings. Although the genetic basis of antibiotic resistance mechanisms has been extensively studied, much less is known about how genetic variation contributes to other aspects of successful infections. Genetic changes that occur during host infection and treatment have the potential to remodel gene expression patterns related to resistance and pathogenesis. Longitudinal sets of multidrug-resistant A. baumannii isolates from eight patients were analyzed by RNA sequencing (RNA-seq) to identify differentially expressed genes and link them to genetic changes contributing to transcriptional variation at both within-patient and population levels...
March 7, 2017: MBio
https://www.readbyqxmd.com/read/28264560/overcoming-an-extremely-drug-resistant-xdr-pathogen-avibactam-restores-susceptibility-to-ceftazidime-for-burkholderia-cepacia-complex-isolates-from-cystic-fibrosis-patients
#17
Krisztina M Papp-Wallace, Scott A Becka, Elise T Zeiser, Nozomi Ohuchi, Maria F Mojica, Julian A Gatta, Monica Falleni, Delfina Tosi, Elisa Borghi, Marisa L Winkler, Brigid M Wilson, John J LiPuma, Michiyoshi Nukaga, Robert A Bonomo
Burkholderia multivorans is a significant health threat to persons with cystic fibrosis (CF). Infections are difficult to treat as this pathogen is inherently resistant to multiple antibiotics. Susceptibility testing of isolates obtained from CF respiratory cultures revealed that single agents selected from different antibiotic classes were unable to inhibit growth. However, all isolates were found to be susceptible to ceftazidime when combined with the novel non-β-lactam β-lactamase inhibitor, avibactam (all minimum inhibitor concentrations (MICs) were ≤8 mg/L of ceftazidime and 4 mg/L of avibactam)...
March 30, 2017: ACS Infectious Diseases
https://www.readbyqxmd.com/read/28170436/the-effect-of-empiric-antimicrobial-treatment-duration-on-detection-of-bacterial-dna-in-sterile-surgical-specimens
#18
John Joseph Farrell, Huaping Wang, Rangarajan Sampath, Kristin S Lowery, Robert A Bonomo
Initial antimicrobial treatment of patients with deep seated or invasive infections is typically empiric. Usually, cultures of specimens obtained from the suspected source of infection are performed to identify pathogens and guide continued antimicrobial treatment. When patients present with signs and symptoms of infection, but sterile body fluid or tissue specimens cannot be obtained in a timely fashion, growth of bacterial pathogens in culture may be inhibited following initiation of empiric antibiotic treatment...
2017: PloS One
https://www.readbyqxmd.com/read/28167547/multicenter-clinical-and-molecular-epidemiological-analysis-of-bacteremia-due-to-carbapenem-resistant-enterobacteriaceae-cre-in-the-cre-epicenter-of-the-united-states
#19
Michael J Satlin, Liang Chen, Gopi Patel, Angela Gomez-Simmonds, Gregory Weston, Angela C Kim, Susan K Seo, Marnie E Rosenthal, Steven J Sperber, Stephen G Jenkins, Camille L Hamula, Anne-Catrin Uhlemann, Michael H Levi, Bettina C Fries, Yi-Wei Tang, Stefan Juretschko, Albert D Rojtman, Tao Hong, Barun Mathema, Michael R Jacobs, Thomas J Walsh, Robert A Bonomo, Barry N Kreiswirth
Although the New York/New Jersey (NY/NJ) area is an epicenter for carbapenem-resistant Enterobacteriaceae (CRE), there are few multicenter studies of CRE from this region. We characterized patients with CRE bacteremia in 2013 at eight NY/NJ medical centers and determined the prevalence of carbapenem resistance among Enterobacteriaceae bloodstream isolates and CRE resistance mechanisms, genetic backgrounds, capsular types (cps), and antimicrobial susceptibilities. Of 121 patients with CRE bacteremia, 50% had cancer or had undergone transplantation...
April 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28167541/can-ceftazidime-avibactam-and-aztreonam-overcome-%C3%AE-lactam-resistance-conferred-by-metallo-%C3%AE-lactamases-in-enterobacteriaceae
#20
Steven Marshall, Andrea M Hujer, Laura J Rojas, Krisztina M Papp-Wallace, Romney M Humphries, Brad Spellberg, Kristine M Hujer, Emma K Marshall, Susan D Rudin, Federico Perez, Brigid M Wilson, Ronald B Wasserman, Linda Chikowski, David L Paterson, Alejandro J Vila, David van Duin, Barry N Kreiswirth, Henry F Chambers, Vance G Fowler, Michael R Jacobs, Mark E Pulse, William J Weiss, Robert A Bonomo
Based upon knowledge of the hydrolytic profile of major β-lactamases found in Gram-negative bacteria, we tested the efficacy of the combination of ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant enteric bacteria possessing metallo-β-lactamases (MBLs). Disk diffusion and agar-based antimicrobial susceptibility testing were initially performed to determine the in vitro efficacy of a unique combination of CAZ-AVI and ATM against 21 representative Enterobacteriaceae isolates with a complex molecular background that included blaIMP, blaNDM, blaOXA-48, blaCTX-M, blaAmpC, and combinations thereof...
April 2017: Antimicrobial Agents and Chemotherapy
keyword
keyword
49890
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"